Japan PPI inflation slips to 11-mth low in July
Investing.com - H.C. Wainwright lowered its price target on Boundless Bio Inc. (NASDAQ:BOLD) to $4.00 from $5.00 on Monday, while maintaining a Buy rating on the ecDNA-directed therapy developer. The new target still represents significant upside from the current trading price of $1.08, with analyst targets ranging from $3 to $5.
The firm cited the announcement that Boundless Bio has opened enrollment for the BBI-355 and BBI-825 combination arm of its Phase 1/2 POTENTIATE trial. This combination uses a once-weekly regimen designed to address hematologic toxicity seen with more frequent BBI-355 dosing and avoid CYP induction observed with twice-daily BBI-825 dosing.
H.C. Wainwright noted that the timeline for initial proof-of-concept data remains on track within the company’s current cash runway, which extends into the first half of 2028. Preclinical studies have shown synergy at exposures expected to be tolerable and selectivity for ecDNA-positive tumors.
The firm maintained its thesis that ecDNA-directed therapies could represent a breakthrough for drug-resistant tumors, with the BBI-355 and BBI-825 combination offering a dual-node inhibition approach in replication stress biology.
H.C. Wainwright indicated that positive updates would include manageable safety at intended weekly doses, clear evidence of CHK1 engagement, and clinically meaningful activity in at least one tumor type, while investors should monitor tumor types enrolled, tolerability across dosing cohorts, and correlation between activity and ecDNA status. With a market capitalization of just $24.17 million, the company’s valuation reflects both the potential and risks of its innovative pipeline.
In other recent news, Boundless Bio Inc. has been the subject of varied analyst opinions. H.C. Wainwright initiated coverage of the company, assigning a Buy rating and setting a price target of $5.00 per share. This positive outlook is based on the potential of Boundless Bio’s extrachromosomal DNA (ecDNA) technology, particularly its CHK1 inhibitor, BBI-355, which aims to tackle drug-resistant tumors. In contrast, Leerink Partners downgraded Boundless Bio’s stock from Outperform to Market Perform, significantly lowering the price target from $15.00 to $3.00. This downgrade follows a reassessment of the company’s lead CHK1 inhibitor program, which has experienced setbacks. Leerink Partners cited the need for Boundless Bio to return to proof-of-principle studies and dose optimization as reasons for dampened expectations. These developments highlight the differing perspectives on Boundless Bio’s potential in the oncology market. Investors may want to consider these recent changes in analyst ratings and price targets when evaluating the company’s prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.